Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project
European isolates collected in 1998 for the Alexander Project were tested for their susceptibility to ciprofloxacin, ofloxacin and a novel fluoroquinolone, gemifloxacin, which has a spectrum of activity including common and atypical respiratory pathogens. MIC<90<s of gemifloxacin for Streptoco...
Saved in:
Published in | Journal of antimicrobial chemotherapy Vol. 46; no. 1; p. 11 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Oxford Publishing Limited (England)
01.07.2000
|
Online Access | Get full text |
Cover
Loading…
Summary: | European isolates collected in 1998 for the Alexander Project were tested for their susceptibility to ciprofloxacin, ofloxacin and a novel fluoroquinolone, gemifloxacin, which has a spectrum of activity including common and atypical respiratory pathogens. MIC<90<s of gemifloxacin for Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis were 0.03, 0.06 and 0.015 mg/L, respectively. On the basis of MIC<90<s, gemifloxacin was the most potent antimicrobial tested against S. pneumoniae and M. catarrhalis. Against H. influenzae, gemifloxacin was one tube dilution more potent than ofloxacin and one tube dilution less potent than ciprofloxacin. As resistance to currently available antimicrobial agents increases, gemifloxacin offers potential as a promising new agent for the treatment of respiratory tract infection. |
---|---|
ISSN: | 0305-7453 1460-2091 |